10-Q Filing

SOLENO THERAPEUTICS INC CIK: 1484565 Q3 2016

Filing Information

Form Type	10-Q
Accession Number	`0001628280-16-021318`
Period End Date	20160930
Filing Date	20161114
Fiscal Year	2016
Fiscal Period	Q3
XBRL Instance	capn-20160930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 53 Income Statement 84 Cash Flow Statement 80

Balance Sheet 53 line items

Line Item	Tag	Value	Unit	Period
Convertible preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.96M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.50M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.42M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	14.02M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	15.76M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$4.72M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	15.76M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$137.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	14.02M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$156.00K	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$35.00K	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$35.00K	USD	Point-in-time
Inventory	`InventoryNet`	$551.00K	USD	Point-in-time
Inventory	`InventoryNet`	$703.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$167.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$217.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$6.40M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$6.51M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$86.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$116.00K	USD	Point-in-time
Goodwill	`Goodwill`	$718.00K	USD	Point-in-time
Goodwill	`Goodwill`	$718.00K	USD	Point-in-time
Other intangible assets, net	`OtherIntangibleAssetsNet`	$917.00K	USD	Point-in-time
Other intangible assets, net	`OtherIntangibleAssetsNet`	$842.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$126.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$76.00K	USD	Point-in-time
Total assets	`Assets`	$8.31M	USD	Point-in-time
Total assets	`Assets`	$8.20M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$695.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$862.00K	USD	Point-in-time
Accrued compensation and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$1.63M	USD	Point-in-time
Accrued compensation and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$915.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.19M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.78M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$196.00K	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$109.00K	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value, 100,000,000 shares authorized, 15,761,530 and 14,017,909 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	`CommonStockValue`	$14.00K	USD	Point-in-time
Common stock, $0.001 par value, 100,000,000 shares authorized, 15,761,530 and 14,017,909 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	`CommonStockValue`	$15.00K	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$89.46M	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$101.39M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-86.25M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-95.70M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$5.71M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$3.22M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$8.31M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$8.20M	USD	Point-in-time

Income Statement 84 line items

Line Item	Tag	Value	Unit	Period
Government grant revenue	`RevenueFromGrants`	$155.00K	USD	1 Quarter
Government grant revenue	`RevenueFromGrants`	-	USD	3 Qtrs
Government grant revenue	`RevenueFromGrants`	$220.00K	USD	3 Qtrs
Government grant revenue	`RevenueFromGrants`	-	USD	1 Quarter
Product revenue	`SalesRevenueGoodsNet`	$92.00K	USD	1 Quarter
Product revenue	`SalesRevenueGoodsNet`	$146.00K	USD	3 Qtrs
Product revenue	`SalesRevenueGoodsNet`	$329.00K	USD	1 Quarter
Product revenue	`SalesRevenueGoodsNet`	$1.17M	USD	3 Qtrs
Total revenue	`SalesRevenueNet`	$329.00K	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$1.17M	USD	3 Qtrs
Total revenue	`SalesRevenueNet`	$247.00K	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$366.00K	USD	3 Qtrs
Cost of product revenue	`CostOfRevenue`	$399.00K	USD	1 Quarter
Cost of product revenue	`CostOfRevenue`	$1.29M	USD	3 Qtrs
Cost of product revenue	`CostOfRevenue`	$96.00K	USD	3 Qtrs
Cost of product revenue	`CostOfRevenue`	$56.00K	USD	1 Quarter
Gross profit (loss)	`GrossProfit`	$191.00K	USD	1 Quarter
Gross profit (loss)	`GrossProfit`	$-70.00K	USD	1 Quarter
Gross profit (loss)	`GrossProfit`	$-120.00K	USD	3 Qtrs
Gross profit (loss)	`GrossProfit`	$270.00K	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.13M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.19M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$4.23M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.25M	USD	3 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$467.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$342.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$1.24M	USD	3 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$1.46M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$1.40M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.43M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$1.71M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.85M	USD	3 Qtrs
Total expenses	`OperatingExpenses`	$10.53M	USD	3 Qtrs
Total expenses	`OperatingExpenses`	$3.37M	USD	1 Quarter
Total expenses	`OperatingExpenses`	$2.87M	USD	1 Quarter
Total expenses	`OperatingExpenses`	$8.92M	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-3.18M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-2.94M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-10.65M	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-8.65M	USD	3 Qtrs
Interest expense, net	`InterestExpense`	-	USD	1 Quarter
Interest expense, net	`InterestExpense`	$1.00K	USD	3 Qtrs
Interest expense, net	`InterestExpense`	-	USD	1 Quarter
Interest expense, net	`InterestExpense`	-	USD	3 Qtrs
Change in fair value of warrants liabilities (expense)	`FairValueAdjustmentOfWarrants`	$-73.00K	USD	1 Quarter
Change in fair value of warrants liabilities (expense)	`FairValueAdjustmentOfWarrants`	$1.18M	USD	3 Qtrs
Change in fair value of warrants liabilities (expense)	`FairValueAdjustmentOfWarrants`	$-200.00K	USD	1 Quarter
Change in fair value of warrants liabilities (expense)	`FairValueAdjustmentOfWarrants`	$-1.32M	USD	3 Qtrs
Cease-use expense	`GainLossOnContractTermination`	-	USD	3 Qtrs
Cease-use expense	`GainLossOnContractTermination`	$-94.00K	USD	3 Qtrs
Cease-use expense	`GainLossOnContractTermination`	-	USD	1 Quarter
Cease-use expense	`GainLossOnContractTermination`	-	USD	1 Quarter
Other expense	`OtherNonrecurringExpense`	$183.00K	USD	1 Quarter
Other expense	`OtherNonrecurringExpense`	$9.00K	USD	1 Quarter
Other expense	`OtherNonrecurringExpense`	$183.00K	USD	3 Qtrs
Other expense	`OtherNonrecurringExpense`	$27.00K	USD	3 Qtrs
Inducement charge for Series C warrants	`PreferredStockConversionsInducements`	-	USD	1 Quarter
Inducement charge for Series C warrants	`PreferredStockConversionsInducements`	$3.05M	USD	3 Qtrs
Inducement charge for Series C warrants	`PreferredStockConversionsInducements`	-	USD	1 Quarter
Inducement charge for Series C warrants	`PreferredStockConversionsInducements`	-	USD	3 Qtrs
Interest and other income (expense), net	`OtherNonoperatingIncomeExpense`	$-110.00K	USD	1 Quarter
Interest and other income (expense), net	`OtherNonoperatingIncomeExpense`	$-4.41M	USD	3 Qtrs
Interest and other income (expense), net	`OtherNonoperatingIncomeExpense`	$1.20M	USD	3 Qtrs
Interest and other income (expense), net	`OtherNonoperatingIncomeExpense`	$191.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-13.06M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-3.29M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-9.45M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-2.75M	USD	1 Quarter
Loss on extinguishment of convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	-	USD	3 Qtrs
Loss on extinguishment of convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	$3.65M	USD	1 Quarter
Loss on extinguishment of convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	-	USD	1 Quarter
Loss on extinguishment of convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	$3.65M	USD	3 Qtrs
Net loss attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-6.40M	USD	1 Quarter
Net loss attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-13.10M	USD	3 Qtrs
Net loss attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-13.06M	USD	3 Qtrs
Net loss attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-3.29M	USD	1 Quarter
Net loss per share attributable to common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-1.60	USD	3 Qtrs
Net loss per share attributable to common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.41	USD	1 Quarter
Net loss per share attributable to common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.33	USD	1 Quarter
Net loss per share attributable to common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.85	USD	3 Qtrs
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	10.04M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	8.18M	shares	3 Qtrs
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	15.76M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	15.36M	shares	3 Qtrs

Cash Flow Statement 80 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-13.06M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-3.29M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-9.45M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-2.75M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$59.00K	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$94.00K	USD	3 Qtrs
Loss on disposition of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-1.00K	USD	3 Qtrs
Loss on disposition of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	3 Qtrs
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$746.00K	USD	3 Qtrs
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$206.00K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$560.00K	USD	3 Qtrs
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$144.00K	USD	1 Quarter
Change in fair value of common stock warrants	`ChangeInFairValueOfCommonStockWarrants`	$-1.32M	USD	3 Qtrs
Change in fair value of common stock warrants	`ChangeInFairValueOfCommonStockWarrants`	$1.18M	USD	3 Qtrs
Inducement charge for Series C warrants	`InducedConversionOfConvertibleDebtExpense`	$3.05M	USD	3 Qtrs
Inducement charge for Series C warrants	`InducedConversionOfConvertibleDebtExpense`	-	USD	3 Qtrs
Non-cash expense of issuing shares to Aspire Capital	`NoncashExpenseOnSharesIssued`	-	USD	3 Qtrs
Non-cash expense of issuing shares to Aspire Capital	`NoncashExpenseOnSharesIssued`	$183.00K	USD	3 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$35.00K	USD	3 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$94.00K	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-19.00K	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$267.00K	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$152.00K	USD	3 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-27.00K	USD	3 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$50.00K	USD	3 Qtrs
Other long-term assets	`IncreaseDecreaseInOtherNoncurrentAssets`	-	USD	3 Qtrs
Other long-term assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$50.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$542.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$175.00K	USD	3 Qtrs
Accrued compensation and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$720.00K	USD	3 Qtrs
Accrued compensation and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-719.00K	USD	3 Qtrs
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$52.00K	USD	3 Qtrs
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	-	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-10.81M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.92M	USD	3 Qtrs
Cash paid for purchase of assets of NeoForce Group, Inc.	`PaymentsToAcquireBusinessesGross`	$1.00M	USD	3 Qtrs
Cash paid for purchase of assets of NeoForce Group, Inc.	`PaymentsToAcquireBusinessesGross`	-	USD	3 Qtrs
Increase in restricted cash	`IncreaseDecreaseInRestrictedCash`	-	USD	3 Qtrs
Increase in restricted cash	`IncreaseDecreaseInRestrictedCash`	$91.00K	USD	3 Qtrs
Cash paid for patent acquisition	`PaymentsToAcquireIntangibleAssets`	$150.00K	USD	3 Qtrs
Cash paid for patent acquisition	`PaymentsToAcquireIntangibleAssets`	-	USD	3 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$48.00K	USD	3 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$39.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.29M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-39.00K	USD	3 Qtrs
Initial public offering costs paid	`PaymentsOfStockIssuanceCosts`	-	USD	3 Qtrs
Initial public offering costs paid	`PaymentsOfStockIssuanceCosts`	$530.00K	USD	3 Qtrs
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$1.43M	USD	3 Qtrs
Proceeds from exercise of common stock options	`ProceedsFromStockOptionsExercised`	$294.00K	USD	3 Qtrs
Proceeds from exercise of common stock options	`ProceedsFromStockOptionsExercised`	$70.00K	USD	3 Qtrs
Repayment of credit line	`RepaymentsOfLinesOfCredit`	$102.00K	USD	3 Qtrs
Repayment of credit line	`RepaymentsOfLinesOfCredit`	-	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$10.77M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$4.97M	USD	3 Qtrs
Net decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-3.24M	USD	3 Qtrs
Net decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-80.00K	USD	3 Qtrs
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$7.96M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$5.50M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$5.42M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$4.72M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$7.96M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$5.50M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$5.42M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$4.72M	USD	Point-in-time
Conversion of Series A preferred to common stock	`ConversionOfStockAmountIssued1`	-	USD	3 Qtrs
Conversion of Series A preferred to common stock	`ConversionOfStockAmountIssued1`	$2.22M	USD	3 Qtrs
Patent costs included in Accrued liabilities	`CapitalExpendituresIncurredButNotYetPaid`	-	USD	3 Qtrs
Patent costs included in Accrued liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$300.00K	USD	3 Qtrs
Stock issuable in consideration for Patent purchase	`StockIssued1`	$112.00K	USD	3 Qtrs
Stock issuable in consideration for Patent purchase	`StockIssued1`	-	USD	3 Qtrs
Reduction in initial public offering costs payable	`ReductionInInitialPublicOfferingCostsPayable`	-	USD	3 Qtrs
Reduction in initial public offering costs payable	`ReductionInInitialPublicOfferingCostsPayable`	$45.00K	USD	3 Qtrs
Cashless exercise of 2010/2012 warrants	`NoncashTransactionExerciseofWarrants`	-	USD	3 Qtrs
Cashless exercise of 2010/2012 warrants	`NoncashTransactionExerciseofWarrants`	$13.00K	USD	3 Qtrs
Series B transaction costs in accounts payable	`TransactionCostsIncludedinAccruedLiabilities`	-	USD	3 Qtrs
Series B transaction costs in accounts payable	`TransactionCostsIncludedinAccruedLiabilities`	$52.00K	USD	3 Qtrs
Fixed asset purchases in accounts payable	`FairValueOfAssetsAcquired`	-	USD	3 Qtrs
Fixed asset purchases in accounts payable	`FairValueOfAssetsAcquired`	$11.00K	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.